Skip to content

Pia croped

 

First U.S. payer coverage - with SciBase CEO Pia Renaudin

Following SciBase’s first U.S. private payer coverage, Pia Renaudin discusses what this milestone means for patients, clinicians, and the company’s ambitions.

Why is the first medical policy such an important milestone for SciBase?

It is a defining milestone and an important step forward in the development of our U.S. business. We have already established strong commercial momentum without broad private payer reimbursement.
The addition of coverage begins to address one of the principal barriers to scaling and expands access to Nevisense for dermatology practices and eligible patients.

What does this mean for patients and dermatologists?

Nevisense provides an objective, high-precision measurement that supports clinicians' melanoma management by detecting melanoma at the most curable stage. For patients, Nevisense could mean fewer unnecessary procedures, and for clinics, Nevisense supports assessing atypical lesions. This first medical policy means we can now start scaling and thus improve patient care. 

Which use of Nevisense does the policy cover?

The policy considers EIS medically necessary when a dermatologist is evaluating a clinically atypical, suspicious pigmented lesion and is considering a biopsy. Melanoma must be part of the differential diagnosis, and specific criteria apply, including the patient’s age, lesion size and location, and the dermatologist’s training.

How does this support SciBase’s long-term ambition?

TThis is an important step towards our ambition to become the global leader in non-invasive, high-precision assessment for cancer detection and skin barrier evaluation. Together, these segments represent an estimated $1 billion market. Our ambition is to capture a significant share of that market, with recurring revenue supporting sustainable growth and supporting our mission to enable better patient care. 

Link to the press release: https://investors.scibase.se/en/press/scibase-has-secured-first-us-payer-coverage-major-insurance-company-aims-global-lead-non

Discover how Nevisense can support your clinical workflow 

Book a personalized demonstration to learn how Nevisense can complement your current diagnostic process and provide objective support for clinical decision-making.